Drug Trial Radar · NCT05027373
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
Last checked: Nov 19, 2026Latest source record: Aug 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
34
Planned (sponsor's estimate)
Start
Aug 13, 2021
Primary completion
Apr 30, 2022
Study completion Sep 30, 2022
Sponsor
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-1β Humanized Monoclonal Antibody injection in Healthy Subjects. Pharmacokinetics, Pharmacodynamics and Anti-drug antibody (ADA) data will be collected; Drug safety, tolerability and immunogenicity for healthy subjects will be evaluated.
Conditions
- Systemic Juvenile Idiopathic Arthritis
- Periodic Fever Syndrome
Interventions
SSGJ-613Drug
SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.
PlaceboDrug
Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: up to 112 days
- TmaxTime frame: up to 112 days
- AUC0-tTime frame: up to 112 days
- t1/2Time frame: up to 112 days
- CL/FTime frame: up to 112 days
- Vd/FTime frame: up to 112 days
- KeTime frame: up to 112 days
- AUC0-∞Time frame: up to 112 days
- AETime frame: up to 112 days
- SAETime frame: up to 112 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui District Central Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.